Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.

In FDA adverse event reports, Wegovy showed the strongest signal for ischaemic optic neuropathy (reporting odds ratio 74.89).

In plain wordsIn FDA safety reports, Wegovy was linked to the strongest signal for an eye nerve problem. A report signal does not prove cause.

Measurements

ROR

74.89 ratio

Wegovy

Source sentences

In FDA adverse event reports, Ozempic showed a signal for ischaemic optic neuropathy (reporting odds ratio 18.81), weaker than Wegovy.

In plain wordsIn FDA safety reports, Ozempic was linked to a signal for an eye nerve problem, weaker than Wegovy. A report signal does not prove cause.

Measurements

ROR

18.81 ratio

Ozempic

Source sentences

In sex-stratified FDA adverse event report analyses, semaglutide showed higher odds of ischaemic optic neuropathy reports in men (reporting odds ratio 116.37).

In plain wordsIn FDA safety reports, semaglutide was linked to higher odds of an eye nerve problem in men. A report signal does not prove cause.

Measurements

ROR

116.37 ratio

men

Source sentences

In multivariable regression of FDA adverse event reports, Wegovy carried greater risk of ischaemic optic neuropathy reports than Ozempic (adjusted OR 4.74).

In plain wordsIn FDA safety reports, Wegovy was linked to more eye nerve problem reports than Ozempic. A report signal does not prove cause.

Measurements

Adjusted OR

4.74 ratio

Wegovy versus Ozempic

Source sentences

In multivariable regression of FDA adverse event reports for semaglutide, men had greater risk of ischaemic optic neuropathy reports than women (adjusted OR 3.33).

In plain wordsIn FDA safety reports for semaglutide, men were linked to more eye nerve problem reports than women. A report signal does not prove cause.

Measurements

Adjusted OR

3.33 ratio

men versus women

Source sentences